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A B S T R A C T
The pathophysiology of functional dyspepsia (FD) remains poorly understood, but alterations of the small in-
testinal microbiome have been observed. The place of probiotics in treatment is uncertain. We performed a
systematic review and meta-analysis of the currently available randomized, controlled trials (RCTs) to evaluate
the potential beneficial effects and risks of probiotics in FD. Pubmed, EMBASE, Scopus, Web of Science and the
Cochrane Controlled Trials Register were searched (up to May 2019) for RCTs evaluating the effects of probiotic
supplementation compared to placebo in adults with FD. Two reviewers independently assessed eligibility, trial
quality and extracted information from identified articles. To compare the effects of probiotics with placebo, risk
ratios (RRs) with 95% confidence intervals (CIs) were pooled using random effects models. Six trials, including
422 participants were included but only three RCTs could be included in the meta-analysis. Lactobacillus strains
showed potential positive effects in terms of improving upper gastrointestinal (GI) symptoms in patients with FD.
Probiotic supplementation tended to improve global dyspepsia score (n = 3 RCTs, risk ratio [RR]: 1.35, 95% CI
0.99 to 1.84; P = 0.061) and bacterial composition in the GI tract. Probiotics were well tolerated without any
serious adverse events. While the available data suggest that supplementation with probiotics may improve GI
symptoms in patients with FD, the evidence is insufficient to draw clear conclusions regarding efficacy. Thus,
high-quality RCTs are needed to establish the beneficial effects of probiotic supplementation on FD outcomes.
1. Introduction
Functional dyspepsia (FD) is a chronic disorder characterised by
recurrent or persistent upper abdominal symptoms that occur mainly
during or after meals (Talley & Ford, 2015). The prevalence of FD
ranges from ~11–30%, depending on the geographic region and the
definition adopted (El‐Serag & Talley, 2004; Zagari et al., 2010). Pri-
mary FD symptoms include postprandial fullness, early satiety, and
epigastric burning and/or pain based on the Rome III. However Rome
III criteria is currently updated as Rome IV criteria(Drossman, 2016)
(Carbone, Holvoet, Vanuytsel, & Tack, 2017). but these patients often
report other symptoms including heartburn, nausea or bloating
(Walker, Potter, & Talley, 2019).
In additition, One of the important diagnosis criteria of FD, is the
absence of organic lesions by routine clinical evaluation(Nishizawa,
Masaoka, & Suzuki, 2016).
The pathophysiology of FD is poorly understood, but altered gas-
trointestinal motility, heightened visceral sensitivity and psychosocial
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factors have all been implicated (Tack, Bisschops, & Sarnelli, 2004).
The treatment of FD is challenging, and no effective cure has been es-
tablished(Talley, 2016). In the majority of cases, symptoms disappear
and return frequently in the long-term, and this adversely affects the
quality of life of patients(Aro et al., 2011). Eradication of H. pylori re-
sults in a small subset with FD experiencing symptom resolution
12 months after treatment, but H. pylori is not associated with specific
FD symptoms (Ronkainen et al., 2019) leading to the speculation the
reason anti-H. pylori therapy is efficacious might be through impacting
the intestinal microbiome rather than only H. pylori, although this is
controversial (Talley, 2016; Talley & Ford, 2015). Other research has
identified subtle duodenal inflammation in FD (characterized by excess
eosinophils) (Talley et al., 2007; Zhong et al., 2017). Diet is one of the
main factors in triggering or exacerbating symptoms in FD(Feinle-Bisset
& Azpiroz, 2013; Filipović et al., 2011; Pilichiewicz, Horowitz,
Holtmann, Talley, & Feinle–Bisset, 2009). Several foods and dietary
components, including coffee, alcohol, citrus fruits, high-fat meals,
carbohydrates, carbonated and soft drinks, and some vegetables, have
been reported to induce symptoms(Mullan et al., 1994; Saito, Locke III,
Weaver, Zinsmeister, & Talley, 2005). Further, diet does alter gut mi-
crobiota composition(Turnbaugh et al., 2009). The non-absorbable
antibiotic rifaximin in one small randomized trial from Hong Kong
improved global dyspepsia symptoms (Tan et al., 2017). There is also
evidence that probiotics may be beneficial for FD (Vandenplas &
Benninga, 2009) but no systematic review has been conducted.
Probiotics are live microbial supplements, which are intended to
have a range of health benefits on the host when consumed in adequate
amounts (AFRC, 1989). Probiotics have been shown to have beneficial
effects in several GI disorders, including diarrhea (Hempel et al., 2012),
constipation (Chmielewska & Szajewska, 2010) and IBS(Brenner,
Moeller, Chey, & Schoenfeld, 2009; Moayyedi et al., 2010). Recent
studies have indicated that probiotic supplementation may significantly
decrease GI symptoms, including nausea, postprandial fullness and
upper GI pain(Gomi et al., 2018; Ianiro et al., 2013). Moreover, studies
on the effects of probiotics in dyspeptic patients who are H. pylori-po-
sitive show that several probiotic bacteria, including Lactobacillus
strains, may have beneficial effects on dyspeptic symptoms by sup-
pressing H. pylori and decreasing related inflammation (Cruchet,
Obregon, Salazar, Diaz, & Gotteland, 2003; Deguchi et al., 2012; Zhang,
Qian, Qin, He, & Zhou, 2015). Another possible mechanism underlying
the effects of probiotics in alleviating FD symptoms may be through
normalization of the disturbed microbiota(Sánchez et al., 2017). We
have therefore performed a comprehensive literature review, which has
revealed six primary studies that have specifically examined the effects
of probiotic supplementation on FD. Thus, the aim of this systematic
review was to assess the up-to-date-evidence on probiotic interventions
for reducing symptoms of FD.
2. Methods
2.1. Literature search
We systematically searched MEDLINE, EMBASE, Cochrane Central
Library, Web of Science and Scopus electronic databases from inception
up to May 2019 to identify randomized, controlled clinical trials (RCTs)
that evaluated the effects of probiotic supplementation on FD symp-
toms. The following search terms were used in combination; ‘functional
dyspepsia’ OR ‘dyspepsia’ OR ‘non-ulcer dyspepsia’ OR ‘functional GI
disorder’ OR ‘epigastric pain’ OR ‘upper GI symptoms’ AND ‘probiotics’
OR ‘prebiotics’ OR ‘synbiotics OR ‘saccharomyces’ OR ‘Lactobacillus’
OR ‘bifidobacterium’. The full search strategy is presented in
***Appendix S1. The electronic searches were supplemented by manual
screening of the references of included papers as well as those of related
reviews. There was no language restriction in the search of databases.
2.2. Study selection
Studies were eligible for inclusion if they were randomized, con-
trolled trials using parallel or cross-over designs and studies that com-
pared the effects of any probiotic, prebiotic or synbiotic intervention
(regardless of dose, type and duration of intervention) with placebo in
adult patients with FD aged 18 years or older, and which evaluated FD
symptoms and their frequency and duration as the primary outcome.
symptoms should defined according to the ROME IV(Drossman, 2016)
criteria’s. Secondary outcomes were adverse events or side effects of
probiotics. In case of cross-over studies we only consider first phrase
before cross-over, to avoid carry-over effect. We exclude review arti-
cles, case reports, case control, cross-sectional and conference pro-
ceedings studies.
2.3. Data extraction and quality assessment
Two reviewers (JH and AA) independently screened all articles
following the guidelines outlined by the Cochrane collaboration
(Higgins & Green, 2008). Inclusion of articles into the systematic review
were determined by the two reviewers, and disagreements were re-
solved with a third reviewer (MS). The following data were extracted
from included articles: first author’s name, year of publication, country
of origin, type and dosage of probiotic intervention, duration of sup-
plementation, participant characteristics, including sex, age and sample
size in intervention and placebo group, as well as main primary and
secondary outcomes of the studies. Methodologic quality assessment of
the included articles was evaluated using the Cochrane risk of bias as-
sessment tools(Higgins et al., 2011).
2.4. Statistical analysis
Meta-analysis was performed using Stata software version 11 (Stata
Corporation, College Station, Texas). The effect size was measured as
the risk ratio (RR) with corresponding 95% confidence intervals (CIs)
obtained by Mantel-Hansel method. Data were combined using the
random-effects model. Heterogeneity of the studies was assessed gra-
phically with forest plots and statistically by chi-square-based Q sta-
tistic and I2 value. Heterogeneity was considered significant at a P-
value of< 0.10 in Q-test or I2 > 40%. Meta-analysis was performed
only when two or more studies reported the same outcome.
3. Results
Fig. 1 presents the PRISMA flow diagram for the selection process of
included studies. An initial search yielded 1695 articles; after removing
duplicates, 1337 titles and abstracts were screened independently by
two researchers (AA and MM). By evaluating the titles and abstracts, an
additional 1313 studies were excluded as irrelevant (animal studies,
unrelated topics or irrelevant design). Of the 24 remaining articles
subjected to full-text evaluation, 18 were excluded (reasons indicated in
Fig. 1), and a total of 6 articles were included in the final review.
The characteristics of the included studies (Emara, Mohamed, &
Abdel-Aziz, 2014; Ianiro et al., 2013; Igarashi et al., 2017; Ohtsu et al.,
2017; Rosania et al., 2012; Takagi et al., 2016) are presented in Table 1.
The studies involved a total of 422 participants and were all published
after 2011. All participants were middle-aged adults (aged
31–50 years), and studies were performed in a variety of geographical
regions (3 in Asia, 2 in Europe and one in Africa). Four studies used a
single strain, i.e. one study used Lactobacillus reuteri(Emara et al., 2014)
and 3 studies used Lactobacillus gasseri OLL2716 (LG21) (Igarashi et al.,
2017; Ohtsu et al., 2017; Takagi et al., 2016), while two further studies
used combinations of probiotic strains (Ianiro et al., 2013; Rosania
et al., 2012). The duration of the probiotic supplementation ranged
from 1 −12 weeks. Thus, there was substantial variability in the de-
signs of these studies.
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3.1. Effect of probiotics on symptoms in functional dyspepsia
Lactobacillus strains showed potential positive effects in terms of
improving upper GI symptoms in patients with FD. Lactobacillus reuteri
significantly decreased the severity of nausea, abdominal pain, acid
regurgitation, abdominal distension, increased flatus after 8 weeks of
supplementation (Emara et al., 2014). In addition, Lactobacillus reuteri
in combination with other probiotics (Lactobacillus rhamnosus and Sac-
charomyces boulardi) reduced postprandial distention and fullness
(Ianiro et al., 2013). Lactobacillus gasseri-fortified yogurt treatment for a
12-week periods significantly improved epigastric pain/discomfort,
postprandial distress and nausea compared with placebo (Ohtsu et al.,
2017). Lactobacillus gasseri improved postprandial fullness, early sa-
tiety, epigastric burning, epigastric bloating, heartburn, reflux feeling
of gastric acid, measured using a 7-point Likert scale, after 12 weeks
intake compared with theplacebo group(Ohtsu et al., 2017). A further
study found an effect of Lactobacillus gasseri on postprandial fullness in
the treatment group compared with the placebo group, however, there
were no statistically significant effect on the other symptoms (Takagi
et al., 2016).
3.2. Effects of probiotic supplementation on H. pylori
Two studies suggested a moderate effect of probiotic supplementa-
tion on H. pylori eradication (Emara et al., 2014; Rosania et al., 2012).
In one study (Emara et al., 2014), Lactobacillus reuteri increased H.
pylori eradication rate by 8.6% (from 74.3% in the treatment group vs.
65.7% in the control group). Moreover, multi-strain probioic supple-
mentation resulted in a 32.5% eradication rate of H. pylori vs. 0% in the
control group(Rosania et al., 2012), Which can be interprete as the
separate effect of probiotic supplementation on H. pylori-associated FD-
like symptoms
3.3. Effects of probiotic supplementation on other GI microbiota
Lactobacillus gasseri supplementation reduced the count of pathogen
bacteria in stool, notably Escherichia/Shigella and Staphylococcus aureus
(Giordani et al., 2019; Itoh, Fujimoto, Kawai, Toba, & Saito, 1995), and
reduced the dominance of Bacteroidetes over Proteobacteria, with the
bacteroides ratio reducing from 7.0 ± 7.6 to 2.2 ± 4.0 after Lacto-
bacillus gasseri supplementation; the bacteroides ratio in healthy sub-
jects was 1.2 ± 1.0. Lactobacillus gasseri also increased Acidobacteria
(Igarashi et al., 2017).
3.4. Effects of probiotic supplementation on inflammation
The severity of gastric inflammation in response to probiotics was
evaluated in one study based on the number of poly- and mono-nuclear
inflammatory cells using a routine pathological grading system(Emara
et al., 2014). The Lactobacillus reuteri treated group showed a greater
reduction in the inflammatory cell score than the placebo-treated group
(p < 0.001). No studies have evaluated duodenal inflammation post
probiotic intervention.
3.5. Adverse events
Generally, probiotics were well tolerated in these studies by the
majority of subjects without any serious adverse events. One study re-
ported minor side effects including diarrhea (one of 35 participants-
treated with Lactobacillus reuteri versus 10 of 35 in control group), taste
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disorder (two of 35 cases versus 8 of 35 in control group) and ab-
dominal distention (5 of 35 versus 4 of 35 in control group). None of the
participants ceased reatment because of them. Moreover, the majority
of these side effects were lower in the probiotic group than in the
placebo group(Emara et al., 2014).
3.6. Risk of bias assessment
The result of the risk of bias assessments for the included studies is
summarized in ***Appendix S2. The included articles were found to
have low (n = 4, (Emara et al., 2014; Ohtsu et al., 2017; Rosania et al.,
2012; Takagi et al., 2016) or high (n = 2) risk of random sequence
generation. Two studies had high risk(Ianiro et al., 2013; Igarashi et al.,
2017), three studies low risk(Emara et al., 2014; Ianiro et al., 2013;
Ohtsu et al., 2017; Rosania et al., 2012), and one was judged to have
unclear risk(Takagi et al., 2016) of bias for randomisation concealment.
There was high risk of performance bias in one study(Igarashi et al.,
2017), and no study was found to have a high risk of attrition bias.
According to the meta-analysis model, there was moderate hetero-
geneity between studies (P = 0.228; I2 = 32.8%) (Fig. 2).
3.7. Meta-analysis
Because of low quality only three studies of six, wer included in
meta-analysis model. Pooling results from three trials (Emara et al.,
2014; Ohtsu et al., 2017; Takagi et al., 2016), which included a control
arm, and included 300 participants (150 cases and 150 controls), there
was a consistent trend for improvement in GI symptoms, including
postprandial fullness, epigastric pain and nausea, in response to pro-
biotics (n = 3 RCTs, RR: 1.35, 95% CI 0.99 to 1.84; P = 0.061, Fig. 2).
4. Discussion
To our knowledge, this is the first systematic review to assess the
role of probiotics in the management of FD symptoms. Taken together,
the results indicate that probiotic supplementation may have beneficial
effects on GI symptoms in FD but the findings are not definitive possibly
reflecting a type II error. However, only a few studies have been per-
formed, and there was significant heterogeneity among the included
studies, particularly in terms of population characteristics, study de-
sign, types of probiotics used, outcome measures and follow up dura-
tion. Thus, the findings must be interpreted with caution, and much
more research is warranted, particularly carefully controlled, long-term
studies to firmly establish the beneficial role for probiotics in the
management and treatment of FD symptoms.
Almost all the probiotics used in the included studies showed po-
sitive effects on improvement of GI symptoms in adult FD patients. The
results of the present review are consistent with prior studies that have
shown probiotics supplementation to be effective at improving lower
digestive tract pain and discomfort (Derwa, Gracie, Hamlin, & Ford,
2017; Didari, Mozaffari, Nikfar, & Abdollahi, 2015; Hempel et al., 2012;
Jin et al., 2018; Korterink et al., 2014; Moayyedi et al., 2010). In
contrast, a previous systematic review of studies in children with IBS
indicated that species, such as Lactobacillus ruteri, were not effective in
reducing the severity or frequency of abdominal pain, although Lacto-
bacillus rhamnosus GG was effective in reducing the severity or fre-
quency of abdominal pain (Ianiro et al., 2013). Interestingly, our sys-
tematic review also indicates that the effects on FD symptoms may also
be strain-specific, and not all probiotics strains ameliorated all symp-
toms. In particular, Lactobacillus gasseri and Lactobacillus reuteri species
may have larger effects on GI symptoms than other lactobacilli strains
but this remains to be established. Clearly, more well-designed RCTs
using standardized outcome measures are needed to identify which
strains, therapy duration and doses, may be most effective.
It is widely acknowledged that acute GI infections caused by bac-
teria, viruses or parasites are major risk factors for FD-related disorders
(Barbara et al., 2016). Studies have shown that the composition of
bacterial flora in the GI tract of people with FD may be significantly
NOTE: Weights are from random effects analysis
Overall  (I-squared = 32.8%, p = 0.226)
Study
ID
Ohtsu (2017)
Emara (2014)
Takagi (2016)
1.35 (0.99, 1.84)
RR (95% CI)
2.03 (1.01, 4.08)
1.13 (0.83, 1.54)
1.43 (0.92, 2.21)
100.00
%
Weight
16.66
49.92
33.42
.35 (0.99, 1.84)
R (95% CI)
.03 (1. 1, 4.08)
.13 (0.83, 1.54)
.43 (0.92, 2.21)
.00
eight
6.66
9.92
3.42
1.245 4.08
Fig. 2. Pooling results from three trials, which compared elimination rate for major FD symptoms between experimental and control.
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different from that of healthy people(Igarashi et al., 2017; Walker et al.,
2019). Thus, one of the putative mechanisms for any benefit of pro-
biotics on FD is their effect on the alteration of GI bacterial composi-
tions (Unno et al., 2015). Eradication of H. pylori infection is one po-
tentially important change in bacterial composition due to
supplementation of probiotics. The results of the current systematic
review indicate that supplementation of probiotics can be effective in
reducing H. pylori infection in a proportion of patients. These results are
consistent with previous studies that demonstrated that probiotics
could be helpful in reducing H. pylori infection (Tong, Ran, Shen,
Zhang, & Xiao, 2007; Zhang et al., 2015; Zhu et al., 2014). Several
mechanisms could explain the H. pylori effects of probiotics. First,
probiotic supplementation may amplify GI innate defence such as by
reinforcing the mucosal barrier function as demonstrated in in vitro and
clinical studies(Salminen, Isolauri, & Salminen, 1996). Second, pro-
biotic supplementation could lead to stimulation of the expression of
gastric mucins which may subsequently prevent H. pylori adherence to
epithelial tissues (Mack, Michail, Wei, McDougall, & Hollingsworth,
1999). Third, probiotic supplementation could modulate the immune
response of the host to H. pylori(Blum, Lesbros-Pantoflickova, &
Corthésy-Theulaz, 2007). However, the observed eradication rate with
a probiotic alone is at best low; perhaps, combination therapy should be
considered in future clinical trials, and the reasons for a lack of greater
effect requires investigation.
Another change that occurs in the stool? composition of GI bacterial
flora following probiotic use is a change in the ratio of Bacteroidetes to
Proteobacteria and the presence of Acidobacteria (Igarashi et al., 2017).
In FD patients, the ratio of Bacteroidetes to Proteobacteria is in favour of
Bacteroidetes (Qiu et al., 2017), and Acidobacteria are absent (Naito,
Fukui, Kashiwagi, & Takagi, 2018). Supplementation of probiotics fa-
cilitated the restoration of Acidobacteria in the GI bacterial flora and
also changed the ratio of Bacteroidetes to Proteobacteria by reducing
Bacteroidetes amount(Igarashi et al., 2017). Whether these changes are
important in driving symptom improvement or are only secondary
phenomena is unknown. Another possible mechanism by which pro-
biotics may improve GI symptoms in FD may relate to their effects on
bile acids. Previous research has shown that gut microbiota promote
deconjugation of bile acids and increase their excretion into the feces.
In addition, gut microbiota also inhibit bile acid synthesis in the liver
(Sayin et al., 2013). Thus, amelioration of upper GI symptoms by pro-
biotics may, in part, be due to their effects on reducing the secretion of
bile acids in the proximal GI tract(Jones, Tomaro-Duchesneau, &
Prakash, 2014).
This systematic review has several strengths. We followed rigorous
systematic review methods as recommended by the Cochrane colla-
boration to decrease possible bias (e.g., two independent reviewers to
search, screen and conduct quality assessment of studies and as well as
extract relevant data). We also did not impose any language restrictions
or time periods. However, some limitations are worth highlighting. In
particular, there was significant variation in the quality of the included
studies. There was also potential risk of bias, such as unclear blinding of
outcomes, in almost all studies. Another limitation was the small
sample size in the majority of included trials. Finally, the Kyoto con-
sensus suggested H. pylori positive dyspepsia responding to eradication
therapy should be considered in a separate category from all other FD
and while this was not possible in the current study, the arbitrary di-
vision remains contentious(Sugano et al., 2015).
In conclusion, the results of this systematic review involving a small
number of studies suggest that supplementation with probiotics could
potentially improve GI dyspeptic symptoms in patients with FD.
However, the available evidence is marred by significant heterogeneity
across the available studies. Further high-quality RCTs are needed to
clarify the effects of probiotic supplementation on FD outcomes.
Moreover, since we could not completely dissect out the direct or in-
direct effect of probiotics on dyspeptic symptoms and H. pylori eradi-
cation, this issue also requires future investigation.
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